All In Biotech

Drug Trial Radar · NCT07393373

Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE

Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

135

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

May 31, 2036

Study completion May 31, 2036

Sponsor

Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.

Conditions

  • Hypochondroplasia

Interventions

  • InfigratinibDrug

    Infigratinib to be administered by mouth and initiated at the last dose level received in the ACCEL 2/3 study or at the dose selected to be further evaluated after proof-of-concept is established for Phase 2 portion of ACCEL 2/3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAE) and serious TEAETime frame: 10 years
  2. Changes over time in standing height Z-score in relation to HCH and non-HCH growth chartsTime frame: 10 years

Locations

24 sites in 10 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    Oakland, California

  • Childrens Hospital Colorado

    Aurora, Colorado

  • Children's National Hospital

    Washington D.C., District of Columbia

  • Johns Hopkins School of Medicine

    Baltimore, Maryland

  • University of Missouri

    Columbia, Missouri

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic

    Madison, Wisconsin

  • Murdoch Children's Research Institute - The Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

  • London Health Sciences Centre - Children's Hospital of Western Ontario

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario Research Institute

    Ottawa, Ontario, Canada

  • Université de Montréal - Centre Hospitalier Universitaire Sainte-Justine

    Montreal, Quebec, Canada

  • Hôpital Femme Mère Enfant

    Bron, France

  • Hôpital Universitaire Necker-Enfants Malades

    Paris, France

  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants

    Toulouse, France

  • Haukeland University Hospital

    Bergen, Norway

  • Paediatric Clinical Research Unit at Oslo University Hospital

    Oslo, Norway

  • Hospital Pediátrico de Coimbra

    Coimbra, Portugal

  • KK Women's and Children's Hospital

    Singapore, Singapore

  • Unidad de Cirugía Artroscopica, Hopsital MIKS

    Vitoria-Gasteiz, Spain

  • Astrid Lindgren Children's Hospital

    Solna, Sweden

  • Manchester University

    Manchester, England, United Kingdom

  • Sheffield Children's Hospital

    Sheffield, England, United Kingdom

  • Glasgow Clinical Research Facility, Queen Elizabeth University Hospital

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.